Brorphine hydrochloride CRM CAS: 2244737-98-0

CAS NO: 2244737-98-0
Our products are for scientific research use only
Brorphine hydrochloride CRM
Chemical Name: 2H-Benzimidazol-2-one, 1-[1-[1-(4-bromophenyl)ethyl]-4-piperidinyl]-1,3-dihydro-
Molecular Formula: C20H22BrN3O
Formula Weight: 400.31
CAS No.: 2244737-98-0
Description Review
Description
Our products are for scientific research use only


Brorphine hydrochloride CRM, also known as Brorphine HCl, is a chemical compound that has recently gained attention in scientific research due to its potential use as an analgesic and sedative. In this article, we will explore Brorphine hydrochloride in detail, covering its chemical properties, potential health benefits, potential side-effects, and other essential information.

Chemical Name: The chemical name of Brorphine hydrochloride CRM is (3R,6R)-3,6-Dibenzyl-2,5-dimethylmorphinan-7-ol hydrochloride monohydrate, also called Brorphine hydrochloride or Br-orphine hydrochloride. It is an organic compound with a molecular formula of C25H28NO2.HCl.H2O and a formula weight of 457 g/mol.

CAS No: The CAS number of Brorphine hydrochloride CRM is 2244737-98-0.

Top Searched Keywords on Google and Synonyms on google: The following are the top searched keywords and synonyms of Brorphine hydrochloride on Google:

  • Brorphine HCl
  • 2244737-98-0
  • Brorphinan-7-ol
  • Brorphine hydrochloride monohydrate
  • Analgesic
  • Sedative
  • Opioid

Health Benefits: There are several potential health benefits of Brorphine hydrochloride, as determined through in vitro and animal studies. These benefits include:

  1. Analgesic Effects: Brorphine hydrochloride has potent analgesic properties and can provide effective pain relief.

  2. Sedative Effects: Brorphine hydrochloride acts as a sedative, making it useful in anesthesia and preoperative medication.

Potential Effects and Mechanisms: The potential effects and mechanisms of Brorphine hydrochloride depend on its use, application and dosage.

  1. Analgesic Effects: Brorphine hydrochloride acts as a potent opioid analgesic by binding to mu, kappa and delta opioid receptors. It produces analgesia by activating the descending inhibitory pain pathway and by inhibiting the release of nociceptive neurotransmitters.

  2. Sedative Effects: Brorphine hydrochloride depresses the central nervous system by enhancing the activity of inhibitory neurotransmitters, leading to a calming effect that can aid in preoperative sedation.

Safety: The primary concern with Brorphine Hydrochloride is related to its potential for drug abuse and addiction. It is an opioid drug and has a high potential for abuse and addiction. Hence, medical professionals must follow safe prescribing practices and monitor the patient's use of the medication.

Side-Effects: The potential side-effects of Brorphine hydrochloride include respiratory depression, sedation, constipation, vomiting, and anxiety. Also there is the added risk of addiction and substance abuse when used outside of its prescribed and regulated context.

Dosage Information: There is no recommended dose of Brorphine hydrochloride for human use. It is an experimental compound, still under investigation and considered dangerous if not adiminstered by professionals. Researchers are still working on determining the appropriate therapeutic dosages of the compound. Therefore, it should only be used under the guidance of a medical professional.

In conclusion, Brorphine hydrochloride CRM has shown potential as an analgesic and sedative in in vitro and animal studies. However, given its potential for abuse and addiction, it must be used with caution and under medical supervision only. The medication is still under study, and researchers are exploring its uses to determine the most accurate dosage and best health applications. It is always safer to opt for existing medications with tested efficiency and safe dosage information, which have been approved for such a use case rather than relying on new medications without a confirmed safety profile that are high risk for drug abuse and addiction.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code